Expression of Human Gaucher Disease Gene GBA Generates Neurodevelopmental Defects and ER Stress in Drosophila Eye

Takahiro Suzuki1,2*, Masami Shimoda3*, Kumpei Ito1,2, Shuji Hanai1, Hidenobu Aizawa1, Tomoki Kato1, Kazunori Kawasaki1, Terumi Yamaguchi3, Hyung Don Ryoo4, Naoko Goto-Inoue5, Mitsutoshi Setou6, Shoji Tsuji7, Norio Ishida1,2*

1 National Institute of Advanced Industrial Science and Technology, Tsukuba, Ibaraki, Japan, 2 Graduate School of Life and Environmental Sciences, University of Tsukuba, Ibaraki, Japan, 3 National Institute of Agrobiological Sciences, Tsukuba, Ibaraki, Japan, 4 Department of Cell Biology, New York University School of Medicine, New York, New York, United States of America, 5 Graduate School of Health Promotion Sciences, Tokyo Metropolitan University, Tokyo, Japan, 6 Department of Cell Biology and Anatomy, Hamamatsu University School of Medicine, Shizuoka, Japan, 7 Department of Neurology, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan.

Abstract

Gaucher disease (GD) is the most common of the lysosomal storage disorders and is caused by defects in the GBA gene encoding glucocerebrosidase (GlcCerase). The accumulation of its substrate, glucoceramide (GlcCer) is considered the main cause of GD. We found here that the expression of human mutated GlcCerase gene (hGBA) that is associated with neuronopathy in GD patients causes neurodevelopmental defects in Drosophila eyes. The data indicate that endoplasmic reticulum (ER) stress was elevated in Drosophila eye carrying mutated hGBAs by using of the ER stress markers dXBP1 and dBIP. We also found that Ambroxol, a potential pharmacological chaperone for mutated hGBAs, can alleviate the neuronopathic phenotype through reducing ER stress. We demonstrate a novel mechanism of neurodevelopmental defects mediated by ER stress through expression of mutants of human GBA gene in the eye of Drosophila.

Introduction

Individuals with Gaucher disease (GD) are deficient in the membrane-associated lysosomal enzyme, glucocerebrosidase (GlcCerase). This reticuloendothelial storage disorder is clinically classified as types 1 (chronic, nonneuronopathic), 2 (acute, neuronopathic) and 3 (chronic, neuronopathic) [1]. Almost 300 mutations have been identified in the human GlcCerase gene (hGBA) [2]. The R120W mutation results in mild disease [3], whereas the L444P mutation is associated with neurological abnormalities [4–9] and the complex allele RecNciI (L444P + A456P + V460V) is involved in acute neurological abnormalities [7,9].

The general treatment of GD is to reduce the accumulation of stored glucoceramide (GlcCer) substrate either by enhancing substrate degradation or by reducing its production. The main treatment strategy is intravenous enzyme replacement, which might partly restore a deficient enzymatic capacity [10]. However this strategy cannot prevent or treat neurological abnormalities, perhaps because GlcCerase cannot cross the blood–brain barrier [11] and therefore no strategies are currently available to treat the neurological abnormalities associated with GD.

Mouse models of GD were generated [12] by creating a GBA null allele [13], a point mutated GBA allele [14] or a GBA conditional knockout [15]. These models based the study on the notion that GD phenotypes are caused by accumulated stored GlcCer. Therefore, mutations or deletions were constructed from the endogenous homologous genes of mouse genome. In some cases, GlcCerase variants are retained to various degrees in the endoplasmic reticulum (ER) as seen in cells of patients with GD [16]. These findings indicated that mutated GlcCerase itself is toxic, but this is yet to be confirmed at molecular level.

Drosophila provides a flexible and powerful model with which to study neurodegenerative diseases [17–21] because most of the genetic pathways involved in normal development and diseases are conserved between Drosophila and mammals. Thus, understanding the molecular mechanisms of neurodegeneration in Drosophila might help to clarify human neurodegenerative processes [22]. Although several models for various neurodegenerative diseases such as Parkinson’s disease have been created [23], a Drosophila model of GD is not available.

Here, we express mutated hGBA in the Drosophila eye using GMR-Gal4. We show that mutated hGBAs in particular, the RecNciI mutation that is associated with acute neurological...
abnormalities in humans, have neurodevelopmental defects in *Drosophila*. We also show that ER stress, which might contribute to neurodegeneration in many disorders [24], was increased in *Drosophila*. Furthermore, the expectorant Ambroxol was identified as a pharmacological chaperone for mutant hGBA [25] that could decrease ER stress and recover the morphological defects in *Drosophila*.

Our data suggest that the expression of mutant hGBA gene results in ER mediated ER stress and neurodevelopmental defects in *Drosophila* eye. Our *Drosophila* transgenic lines can serve as a powerful tool for investigating the mechanisms of neurodegeneration as well as novel therapeutic targets of GD.

Materials and Methods

Human GBA cDNAs

Human GBA cDNAs (WT, R120W and RecNci) were generous gifts from Professor Shoji Tsuji at the University of Tokyo.

Production of transgenic flies

Transgenic flies were generated as described [26] using pUAST vectors harboring hGBA cDNAs. The vectors were injected into *yw Drosophila melanogaster* embryos using the helper plasmid pTr25.7wc that encodes a transposase. One hGBAWT, two independent hGBA R120W and three independent hGBA RecNci lines were generated. All recombinant DNA experiments proceeded under the approval of the AIST Recombinant DNA Committee.

Isolation of RNA and quantitative RT-PCR

Flies were entrained at 25°C under LD (light:dark, 12:12 h) and then three-day-old male heads (Genotype: w;GMRI-GALA/CyO:UAS-hGBA) were analyzed. Male flies were normally entrained at 25°C under LD and continuously heat-shocked at 37°C twice daily for 0.5 h (at 9 am and 9 pm) for studies using the hs-GAL4 driver. Whole males (Genotype: w;hs-GAL4/CyO:UAS-hGBA/+4) were collected three hours after the last shock. Fly heads or whole flies were homogenized in TRIzol reagent (Invitrogen, Carlsbad, California), mixed with 25% chloroform and then separated by centrifugation at 12,000×g for 15 min in 4°C. Supernatants were mixed with an equal volume of 2-propanol, separated by centrifugation at 12,000 g for 10 min at 4°C and then the pellets were mixed with 70% ethanol and separated by centrifugation at 7500×g for 3 min at 4°C. The pellets were mixed with dH2O. Complementary DNAs were synthesized using the Prime Script RT Reagent Kit (Takara Bio, Otsu, Japan) according to the manufacturer’s protocol. The cDNA levels of the hGBA, dBiP and dRpl32 genes were measured by quantitative RT-PCR using a LightCycler (Roche Applied Science) with SYBR Premix Ex Taq (Takara Bio, Otsu, Japan). The amount of mRNA was corrected relative to that of dRpl32. Table 1 shows the sequences of the primer pairs.

Western blotting

Western blotting proceeded as described [26]. All transgenic combinations were entrained at 25°C under LD, and then the heads of flies with the w;GMRI-GALA/CyO:UAS-hGBA genotype collected at 11.00 a.m. were homogenized in extraction buffer containing 20 mM HEPES (pH 7.5), 100 mM KCl, 5% glycerol, 100 mM Na3VO4, 0.5 M EDTA, 0.1% Triton-X, 10 mg/mL antipain, 10 mg/mL pepstatin-A, 10 mg/mL leupeptin, 24 TIU/mL aprotinin and 0.1 M phenylmethyl-sulfonyl-fluoride (PMSF). The samples were separated by centrifugation at 20,000×g for 5 min at 4°C. The protein concentration in each supernatant was determined using the BCA protein assay reagent (PIERCE, Rockville, MD, USA). The extracts were mixed with same volume of SDS-PAGE sample buffer containing 5% mercaptoethanol, boiled for three minutes and quickly cooled. Proteins (30 μg) from extracts resolved by electrophoresis on 10% SDS-PAGE gels were electrophoretically transferred to ECL Hybond membranes (Amersham) using a carbon electrode for 90 min at 1 mA/cm² and then probed for hGBA using the b55080 anti-GBA (1:2000) antibody (Abcam). Secondary HRP-labeled anti-mouse antibody was diluted 1:10,000 and signals were detected using ECL+p+TM (Amersham).

Scanning electron microscopy

Three-day-old males with the w;GMRI-GALA/CyO:UAS-hGBA genotype from each experimental transgenic were fixed in 2% glutaraldehyde/0.1 M phosphate buffered saline (PBS) for 12 h at 4°C. The samples were washed with 0.1 M PBS, sequentially dehydrated in 50%–100% ethanol and freeze-dried for 12 h at 4°C. The dried samples were placed on a specimen stage and coated with osmium tetroxide using a PMC-5000 plasma ion coater (Meiwa- fosis Co., Tokyo, Japan). The *Drosophila* heads were examined by scanning electron microscopy (S-5000, Hitachi High-Technologies Co., Tokyo, Japan) at 5 kV.

Immunohistochemistry

All transgenic combinations were entrained at 25°C under LD, and then the eye imaginal discs of third instar larvae with the w;GMRI-GALA/CyO:UAS-hGBA/TM6B genotype were fixed in Mildform 10N (Wako Pure Chemical Industries, Osaka, Japan) for 12 h at 4°C. The fixed discs were washed with PBST and probed for EGFP using the A6455 anti-GFP (1:2000) antibody (Invitrogen). Alexa Fluor 488 anti-rabbit secondary antibody was added and then the discs were examined by confocal laser scanning microscopy (Zeiss LSM700, Zeiss LSM5, OLYMPUS FV1000MPE). Values for fixed quantities of fluorescence intensity were measured using ImageJ.
Ambroxol treatment

All transgenic combinations were maintained on yeast-glucose-agar medium containing Ambroxol hydrochloride (WAKO 013-18943) /DMSO (WAKO 043-07216) to final concentrations of 0 and 1 mM. The final concentration of DMSO in the medium was 0.1%. All transgenic combinations were entrained at 25°C under LD. Thereafter, the eye imaginal discs of third instar larvae of the genotype, w;GMR-GAL4/UAS-xbp1-EGFP;UAS-hGBA/TM6B were analyzed immunohistochemically, heads from three-day-old males with the w;GMR-GAL4/CyO;UAS-hGBA genotype were analyzed by quantitative RT-PCR and three-day-old males (Genotype: w;GMR-GAL4/CyO;UAS-hGBA) were analyzed using scanning electron microscopy.

Statistical analysis

We verified differences in variance of the sizes of ocelli using dispersion analysis (Levene’s test). Other Statistical findings were analyzed using Student’s t test. The statistical significance of a difference between each transgenic combination was determined on the basis of a P-value, 0.05. P-values of <0.05, 0.01 or 0.001 are described as **P<0.05, ***P<0.01, or ****P<0.001, respectively.

Results

Generation of transgenic flies carrying hGBA variants

We introduced wild type hGBAs (hGBA WT) as well as hGBAs with R120W (hGBA R120W) and RecNciI (hGBA RecNciI) mutations into Drosophila to investigate molecular mechanism of GD. Figure 1A shows the amino acid sequences of the normal and mutated hGBAs seen in patients. The R120W mutation exerts mild effects [3], whereas RecNciI is associated with acute neurological abnormalities [7,9]. We ligated the UAS promoter to hGBA to use the GAL4-UAS system that allows targeted, tissue-specific gene expression when transgenic flies bearing a UAS transgene are crossed with fly lines that express GAL4 [28]. One hGBA WT (hGBA WT L10 where 10 is the line number), two hGBA R120W (hGBA R120W L19 , hGBA R120W L21 ) and three hGBA RecNciI (hGBA RecNciI L01 , hGBA RecNciI L04 , hGBA RecNciI L08) lines of flies were generated.

We crossed each line with the GMR-GAL4 line, which drives the gene downstream of UAS in all Drosophila eye cells posterior to the furrow, including photoreceptor neurons and pigment cells [29]. The findings of quantitative RT-PCR and Western blotting showed that the transgenic flies expressed various levels of mRNA and proteins (Figure 1B and C). Protein expression was almost identical between the two hGBA R120W and the three hGBA RecNciI transgenic combinations. Western blotting showed a significant decrease in the total amount of hGBA protein in the hGBA RecNciI transgenic combinations compared with the other transgenic combinations, because the RecNciI mutation includes L444P that is associated with protein degradation in patients with GD [30].

Expression of hGBA carrying the RecNciI mutation causes neurodevelopmental defects in the Drosophila eye

We investigated morphological phenotypes using scanning electron microscopy to examine ectopic expression of mutated hGBAs in Drosophila eyes (Figure 2A). This is useful for observing the effects of expressed genes that are associated with neurodegenerative disease [17–21]. Overexpressing the hGBA WT gene and hGBA R120W gene in the eyes of the Drosophila transgenic combinations slightly affected eye morphology. In contrast, all hGBA RecNciI transgenic combinations had an extreme, rough-eye phenotype. Dispersion analysis revealed obvious differences in variance of the sizes of ocelli between the hGBA RecNciI transgenic combinations and the GMR control (Figure 2B). These results
showed that hGBA with the RecNcil mutation was observed the most severe phenotype of the neurodevelopmental defects.

Endoplasmic reticulum (ER) stress is detected in hGBR transgenic flies

We investigated whether or not the hGBA expressing transgenic flies show ER stress by using the ER stress marker, xbp1-EGFP, in which EGFP is expressed in frame only after ER stress [31].

We produced experimental fly combinations containing GMR-GAL4, UAS-hGBA and UAS-xbp1-EGFP and then evaluated the levels of EGFP fluorescence in the eye imaginal discs of third larval instar (Figure 3A). The hGBA<sup>RecNcil</sup> transgenic combinations showed high fluorescence intensity. Fluorescence intensity was detected in the order of hGBA<sup>RecNcil</sup> > hGBA<sup>R120W</sup> > hGBA<sup>WT</sup> expressing flies. Figure 3B summarizes fluorescence intensity. These results correlated well with the levels of morphological defects in the eyes of transgenic flies, suggesting that ER stress is one of main factors of the morphological abnormalities detected in hGBR transgenic flies.

To confirm the above findings, we evaluated the expression of another ER stress marker, dbiP gene, which is a major ER chaperone [32]. Quantitative RT-PCR showed that dbiP mRNA expression in the hGBA<sup>R120W</sup> and hGBA<sup>RecNcil</sup> transgenic combinations was upregulated 1.3–1.7-fold (Figure 3C). We confirmed these findings using a different driver, and crossed flies with the hs-GAL4 driver with UAS-hGBA flies that express high levels of dbiP mRNA throughout the body when heat-shocked.
Expression levels of dBiP mRNA were 2.5–4.2-fold higher in the hGBAR120W and hGBARecNciI transgenic combinations than in the control and hGBAWT transgenic combinations (Figure 3D). These data suggest that mutated hGBAs cause ER stress not only in the eyes, but also in the whole body of Drosophila.

Ambroxol can recover the morphological defects and decrease ER stress in hGBA transgenic flies

Ambroxol is an FDA-approved expectorant that enhances the stabilization and trafficking of mutated GlcCerase and it works as a pharmacological chaperone in fibroblasts from patients with GD [25,30]. We therefore tested that Ambroxol can decrease ER stress in hGBA transgenic flies with standard fly food containing Ambroxol. We evaluated EGFP fluorescence intensity in the eye imaginal discs of third instar larvae and dBiP mRNA expression in three-day-old adult male heads. Ambroxol decreased EGFP fluorescence intensity (Figure 4A and B) and dBiP mRNA expression in hGBAR120W and hGBARecNciI transgenic combinations were upregulated (n = about 30 fly heads per transgenic combination). Internal control was dRpl32. Error bars represent SE. *Significant difference compared with values from GMR control (***P<0.001; Student’s t test). (C) Endoplasmic reticulum stress marker gene, dBiP (major ER chaperone) mRNA expression in hGBAR120W and hGBARecNciI transgenic combinations was upregulated (n = about 30 fly heads per transgenic combination). Internal control was dRpl32. Error bars represent SE. *Significant difference compared with GMR control (*P<0.05; Student’s t test). (D) High levels of HGBAs are expressed in whole bodies of heat-shocked flies. Expression levels of dBiP mRNA of hGBAR120W and hGBARecNciI transgenic combinations were also upregulated (n = about 30 flies per transgenic combination). Internal control was dRpl32. Error bars represent SE. *Significant difference compared with hs control (*P<0.05; **P<0.01; ***P<0.001; Student’s t test).

doi:10.1371/journal.pone.0069147.g003
Neurodevelopmental defects in *Drosophila* eyes caused by hGBA with RecNciI mutation

Here, we showed that hGBA with the RecNciI mutation, which caused type 2 GD (acute neurological abnormalities in humans), showed severe neurodevelopmental defects in *Drosophila* eyes. The primary defect in GD is an obvious deficiency in the activity of the lysosomal enzyme GlcCerase [33]. Deficiencies in GlcCerase result in the accumulation of its lipid substrate GlcCer in the lysosomal compartment of macrophages [10]. The defects associated with GD are thought to be caused by GlcCer accumulation. In fact, mouse models of GD based the study on the notion that GD phenotypes are caused by accumulated stored GlcCer. Therefore, mutations or deletions were constructed from the endogenous homologous genes of mouse genome. In some cases, GlcCerase variants are retained to various degrees in the ER, as seen in cells of patients with GD [16]. These findings suggested that mutated GlcCerase itself is toxic, but this is yet to be confirmed at molecular level. Our *Drosophila* transgenic lines can serve as a powerful tool for investigating molecular mechanisms of neurodegeneration as well as novel therapeutic targets of GD, because our work suggests that ER stress, due to misfolding of the GlcCer protein, may be a contributory factor in the pathology of GD.

Discussion

Neurodevelopmental defects in *Drosophila* eyes caused by hGBA with RecNciI mutation

Ambroxol can recover morphological defects and decrease ER stress in transgenic flies. (A) Less fluorescence emitted by the eye imaginal discs of hGBARecNciI transgenic combinations treated with, than without 1 mM Ambroxol. (B) Values generated by different transgenic combinations at fixed quantities of fluorescence intensity (n = 12–43 eye imaginal discs of third instar larvae per transgenic combination). Error bars represent SE. *Significant difference compared with controls (all without Ambroxol) (**P < 0.001; Student’s t test). (C) Ambroxol (1 mM) decreases expression levels of dBIP mRNA in the heads of hGBARecNciI transgenic combinations (n = about 30 fly heads per transgenic combination). Internal control was dRpl32. Error bars represent SE. (D) Eye phenotypes of hGBARecNciI transgenic combinations incubated without or with 1 mM Ambroxol. Size and shape of ocelli were uniform, and layout uniformity was more similar to that of normal fly eyes treated with 1 mM Ambroxol. (E) Size histograms of ocelli in hGBARecNciI transgenic combinations treated with or without 1 mM Ambroxol. (n = 6–10 flies per transgenic combination; about 400 ocelli each). Dispersion analysis showed significant differences from hGBARecNciI transgenic combinations treated with and without 1 mM Ambroxol (F = 2.07–3.35; P < 0.001; Levene’s test).

DOI:10.1371/journal.pone.0069147.g004
Endoplasmic reticulum (ER) stress is a key mechanism of neurodevelopmental defects

We found here that mutated hGBAs cause ER stress as well as neurodevelopmental defects in Drosophila eyes, which suggest that protein products of GcERase might be toxic to the ER. This findings suggest that mutated GlcERase could serve as a new therapeutic target for type 2 GD. ER stress contributes to neurodegeneration across a range of neurodegenerative disorders [24] and it might also be responsible for neurodegeneration in the eyes of Drosophila transfected with hGBAs, especially when they harbor the RecNeI mutation that is associated with acute neurological abnormalities in GD patients [7,9]. Previous reports indicated that ER stress is a common mediator of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders including GD [34]. Unfolded protein response activation observed in fibroblast cells from neuronomopathic GD patients might be a common mediator of apoptosis in neurodegenerative lysosomal storage disorders. This suggests that mutated hGBAs may cause apoptosis through ER stress in Drosophila eyes.

Ambroxol ameliorates neurodevelopmental defects and decreases ER stress induced by mutant hGBA expression in Drosophila eye

Ambroxol is known as a pharmacological chaperone for mutant glucocerebrosidase including the L444P point mutation [30]. Our results showed that Ambroxol can decrease ER stress and ameliorate neurodevelopmental defects in Drosophila with the RecNeI mutation. The complex allele RecNeI also includes L444P point mutation. The data suggests that Ambroxol acts as a pharmacological chaperone for the RecNeI GlcERase variant in Drosophila eye. As ER stress contributes to neurodegeneration across a range of neurodegenerative disorders [24], Ambroxol may have an important use in ameliorating neurodegeneration in GD patients.

Acknowledgments

We thank Professor Shoji Tsuji at the University of Tokyo for the gift of the hGBA cDNAs. Stocks of GMR-GAL4 flies were obtained from the National Institute of Genetics Fly Stock Center (Shizuoka, Japan). Stocks of hs-GAL4, CG31414[Ml], CG31148[Ml], elav-GAL4, UAS-SNCA-WT, UAS-SNCA-A35T and UAS-SNCA-A30P flies were obtained from the Bloomington Stock Center (Bloomington, IN, USA).

Author Contributions

Conceived and designed the experiments: TS M. Shimoda NL. Performed the experiments: TS TK. Analyzed the data: TS. Contributed reagents/materials/analysis tools: M. Shimoda HDR ST NI. Wrote the paper: TS M. Shimoda. Guided the experiments: KI SH KA TY NG M. Setou ST. Provided substantial input into the writing of the manuscript: ST NI.

References

1. Ginns EI, Choudary PV, Tsuji S, Martin B, Stubblefield B, et al. (1985) Gene mapping and leader polypeptide sequence of human glucocerebrosidase: implications for Gaucher disease. Proc Natl Acad Sci U S A 82: 7101–7105.

2. Hroska KS, LaMarca ME, Scott CR, Sfidanosky E (2008) Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat 29: 567–583.

3. Wan I, Hsu CM, Tsai CH, Lee CC, Hwu WL, et al. (2006) Mutation analysis of Gaucher disease patients in Taiwan: high prevalence of the RecNeI and L444 mutations. Blood Cells Mol Dis 36: 422–425.

4. Tsuji S, Choudary PV, Martin BM, Stubblefield BK, Mayer JA, et al. (1987) A mutation in the human glucocerebrosidase gene in neurodergative Gaucher’s disease. N Engl J Med 316: 570–573.

5. Theophilos B, Latham T, Grabowski GA, Smith FI (1989) Gaucher disease: molecular heterogeneity and phenotype-genotype correlations. Am J Hum Genet 45: 212–225.

6. Dahl N, Lagervall M, Erikson A, Persson U (1990) Gaucher disease type III (Norrbottian type) is caused by a single mutation in exon 10 of the glucocerebrosidase gene. Am J Hum Genet 47: 275–278.

7. Ida H, Rennert OM, Iwasawa K, Kobayashi M, Eto Y (1999) Clinical and genetic heterogeneity of Japanese Gaucher’s disease patients. Am J Hum Genet 64: 1777–1786.

8. Choy FY, Zhang W, Shi HP, Zay A, Campbell T (2007) Gaucher disease among Chinese patients: review on genotype/phenotype-genotype correlation. Am J Hum Genet 80: 257–293.

9. Aerts JM, Kallenneij WW, Vegdam W, Joos Ferra M, van Breemen MJ, et al. (2011) Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies. J Inherit Metab Dis 34: 605–619.

10. Schifflmann R, Heyes MP, Aerts JM, Dambrosia JM, Patterson MC, et al. (1997) Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet 66: 471–483.

11. Furumura N, Saito K, Oka E, Yagi S, Nishimura M, et al. (2006) Identification and characterization of ambroxol as an enzyme enhancement therapy in a murine model of Gaucher disease. J Biol Chem 281: 23052–23058.

12. Farfel-Becker T, Vitner EB, Futerman AH (2011) Animal models for Gaucher disease. Dis Model Mech 4: 746–752.

13. Tybulewicz VL, Tremblay ML, LaMarca ME, Willemsen R, Stubblefield BK, et al. (1992) Animal model of Gaucher’s disease from targeted disruption of the mouse glucocerebrosidase gene. Nature 357: 407–410.

14. Ellis MC, O’Neill EM, Rubin GM (1993) Expression of D. melanogaster and human glucocerebrosidase in the Drosophila L444P mutant. Mol Biol Med 10: 783–791.

15. Maegawa GH, Tropak MB, Buttner JD, Rigat BA, Fuller MJ, et al. (2007) Unfolded proteins and Endoplasmic Reticulum stress in neurodegenerative disorders. J Cell Biol 175: 775–785.

16. Ron I, Horowitz M (2005) ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum Mol Genet 14: 2387–2398.

17. Chan HY, Bonini NM (2000) Drosophila models of human neurodegenerative disease. Cell Death Differ 7: 1075–1100.

18. Takeyama K, Ito S, Yamamoto A, Tanimoto H, Furutani T, et al. (2002) Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron 35: 853–864.

19. Sang TK, Jackson GR (2005) Drosophila models of neurodegenerative disease. Neurobiol 2: 438–446.

20. Lu B, Vogel H (2009) Drosophila models of neurodegenerative diseases. Annu Rev Pathol 4: 315–342.

21. Sang TK, Jackson GR (2005) Drosophila models of human neurodegenerative disease. Cell 122: 1031–1034.

22. Fernandez-Fuente P, Nino-Rosales ML, de Geonoy B, She WC, Luchak JM, et al. (2009) Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 460: 101–106.

23. Feany MB, Bender WW (2000) A Drosophila model of Parkinson’s disease. Nature 404: 394–398.

24. Dong KM, Kennedy D, Gorman AM, Gupta S, Holy SJ, et al. (2011) Unfolded proteins and Endoplasmic Reticulum stress in neurodegenerative disorders. J Cell Mol Med 15: 2025–2039.

25. Margava GH, Tropak MB, Buttner JD, Rigat BA, Fuller M, et al. (2009) Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J Biol Chem 284: 23052–23058.

26. Nishinokubi I, Shimoda M, Kako K, Sakai T, Fukamizu A, et al. (2003) Highly conserved Drosophila ananasase like gene functions as a clock component in Drosophila melanogaster. Gene 307: 183–190.

27. Inoue TA (2006) Morphology of dorsoventral surfaces of Japanese Papilio butterflies and relations between these morphology, phylogeny and hostplant preferring hierarchy. Zoolog Sci 23: 169–189.

28. Brand AH, Perrimon N (1993) Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development 118: 401–415.

29. Ellis MC, O’Neill EM, Rubin GM (1993) Expression of Drosophila glass protein and evidence for negative regulation of its activity in non-neuronal cells by another DNA-binding protein. Development 119: 153–165.

30. Bendover-Ber I, Ron I, Flocan E, Horowicz M (2011) Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant. Blood Cells Mol Dis 46: 4–10.

31. Nyose TA (2006) Morphology of dorsoventral surfaces of Japanese Papilio butterflies and relations between these morphology, phylogeny and hostplant preferring hierarchy. Zoolog Sci 23: 169–189.

32. Plongthongkum N, Kullawong N, Panyim S, Tirasophon W (2007) Ire1 mediated regulation of XBP1 mRNA splicing is essential for the unfolded protein response (UPR) in Drosophila melanogaster. Biochem Biophys Res Commun 354: 789–794.

33. Brady RO, Kaufer JN, Bradley RM, Shapiro D (1966) Demonstration of a deficiency of glucocerebroside-degrading enzyme in Gaucher’s disease. J Clin Invest 45: 1112–1115.

34. Wei H, Kim SJ, Zhang Z, Tsai PC, Winiarski KE, et al. (2008) ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative
and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones. Hum Mol Genet 17: 469–477.

35. Takehana A, Katsuyama T, Yano T, Oshima Y, Takada H, et al. (2002) Overexpression of a pattern-recognition receptor, peptidoglycan-recognition protein-LE, activates imd/relish-mediated antibacterial defense and the prophenoloxidase cascade in Drosophila larvae. Proc Natl Acad Sci U S A 15: 13705–13710.